Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

T(H)17 cytokines in autoimmune neuro-inflammation.
Episode 22 with Dr. Paul Matthews discussing the Optimize project in the UK
Gender and the hygiene hypothesis.
HLA-DRB1*15:01 and multiple sclerosis: a female association?
ECTRIMS 2015
Granulocyte macrophage colony-stimulating factor: a new putative therapeutic target in multiple sclerosis.
Sex ratio of multiple sclerosis and clinical phenotype.
Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) and the Cooperative Meeting with Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)
MS Research Roundup: January 29, 2014
National MS Society: Postdoctoral Fellowships
Episode 38 with Dr. Joseph Berger on progressive multifocal leukoencephalopathy
Episode 56 with Dr. Gavin Giovannoni, on early phase 3 results of ocrelizumab, the first experimental drug to show some benefit in a progressive form of multiple sclerosis in a major trial
MS Research Roundup: January 31, 2014
Synthetic Biologics Reports UCLA Announcement of Preliminary Positive Topline Efficacy and Safety Results from Investigator-Led Phase II Study of Trimesta™ for RRMS
Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial.
Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis.
Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis.
ACTRIMS-ECTRIMS 2014 -- Day 1, afternoon
Best practice in the use of natalizumab in multiple sclerosis.
Natalizumab strongly suppresses cortical pathology in relapsing-remitting multiple sclerosis.
Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT.
[Usefulness of electronic drug registers: Spanish register of patients treated with fingolimod (Gilenya ®)].
Blood Brain Barrier Meeting
Testosterone treatment in multiple sclerosis: a pilot study.
US patent office grants patent claiming dosing regimen for TECFIDERA™ (dimethyl fumarate)

Pages